Avidity Biosciences, INC 8-K filings

Atrium Therapeutics reported Q2 2026 results, highlighting FDA IND clearance for ATR 1072, initiation of the Corventis trial, and a $15 million milestone payment from Bristol Myers Squibb.

Atrium Therapeutics has received FDA clearance for its Investigational New Drug application, enabling the Corventis Phase 1/2 clinical trial for ATR 1072 to treat PRKAG2 syndrome.

Novartis AG has completed its acquisition of Avidity Biosciences, Inc. for $72.00 per share in cash, following a pre-merger spin-off of Avidity's early-stage cardiology programs into Atrium Therapeutics, Inc.

Avidity Biosciences stockholders overwhelmingly approved the merger agreement with Novartis AG and the separation agreement for Atrium Therapeutics, satisfying a key transaction condition.

Avidity Biosciences has adjourned its special stockholder meeting to February 26, 2026, to finalize conditions for the SpinCo distribution, with the Novartis merger now expected to close on February 27, 2026.

Avidity Biosciences announced February 12, 2026, as the record date for the pro rata distribution of Atrium Therapeutics shares to stockholders, preceding its acquisition by Novartis AG.

Avidity Biosciences secures early HSR Act termination and accelerates executive compensation ahead of its merger with Novartis AG.

Avidity Biosciences announced its acquisition by Novartis for approximately $12 billion, alongside positive Q3 2025 financial results and significant clinical progress for its RNA therapeutics pipeline.

Novartis AG will acquire Avidity Biosciences for $72.00 per share in cash, valuing the company at approximately $12.0 billion, while Avidity's early-stage cardiology programs will spin off into a new publicly traded entity, SpinCo.

Avidity Biosciences announced a delay in its Biologics License Application submission for del-zota to the first quarter of 2026, requiring additional non-clinical data for the FDA.

Avidity Biosciences, a biopharmaceutical company, priced an upsized public offering of 15 million common shares at $40.00 each, expecting $600 million in gross proceeds to fund clinical programs and commercial expansion.

Avidity Biosciences announced positive one-year data from its del-zota trials for Duchenne Muscular Dystrophy, showing significant functional improvements and biomarker changes, and plans for a year-end BLA submission.

Avidity Biosciences entered a significant manufacturing agreement with Lonza and reported its second-quarter 2025 financial results, highlighting clinical progress and a strong cash position.

Avidity Biosciences announced that its Duchenne muscular dystrophy treatment, delpacibart zotadirsen, received Breakthrough Therapy designation from the FDA, keeping it on track for a year-end 2025 Biologics License Application submission.

Avidity Biosciences, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting of Stockholders, including the re-election of three Class II directors, the ratification of Deloitte & Touche, LLP as its independent auditor, and the advisory approval of named executive officer compensation.

Avidity Biosciences announced that the FDA has opened an accelerated approval pathway for delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD), alongside positive topline data from its Phase 1/2 FORTITUDE trial and the initiation of its global confirmatory Phase 3 FORWARD study.

Avidity Biosciences announces its Q1 2025 financial results, highlighting progress in clinical trials and commercial preparations, with a strong cash position to support its programs.

Avidity Biosciences has replaced BDO USA with Deloitte & Touche LLP as its independent registered public accounting firm for the year ending December 31, 2025, effective after filing the Q1 Form 10-Q.

Avidity Biosciences has exercised its option to lease an additional 80,000 square feet, expanding its corporate headquarters with a $53.7 million commitment.

Avidity Biosciences reports positive topline data from its Phase 1/2 EXPLORE44 trial of delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD44), showing promising results in dystrophin production and safety.

Avidity Biosciences announces its Q4 2024 financial results, highlighting progress in its three clinical programs for rare neuromuscular diseases and anticipating major milestones in 2025, including a planned BLA submission.

Avidity Biosciences has outlined its clinical and regulatory plans for 2025, including BLA submissions and key data readouts for its pipeline of treatments for muscular dystrophies.

Avidity Biosciences announced its initial precision cardiology development candidates, AOC 1072 and AOC 1086, along with advancements in its next-generation RNA technology.

Avidity Biosciences announced positive clinical trial results for its del-zota program, progress in other clinical trials, and a strong cash position of $1.6 billion in its third quarter 2024 financial results.

Avidity Biosciences has commenced the biomarker cohort of its Phase 1/2 FORTITUDE trial for delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy (FSHD).

Avidity Biosciences has announced that the U.S. Food and Drug Administration has removed the partial clinical hold on their drug delpacibart etedesiran.

Avidity Biosciences has priced an upsized public offering of 7,320,000 shares of common stock at $41.00 per share, expecting gross proceeds of approximately $300.1 million.

Avidity Biosciences announced positive results from multiple clinical trials, including significant increases in dystrophin production and reductions in DUX4 regulated genes, alongside a strong cash position of approximately $1.3 billion.

Avidity Biosciences reported positive initial results from its EXPLORE44 trial, showing significant improvements in key biomarkers for Duchenne muscular dystrophy patients treated with delpacibart zotadirsen.

Avidity Biosciences held its 2024 Annual Meeting on June 13, 2024, electing three Class I directors and ratifying the appointment of BDO USA, P.C. as its independent auditor.